Drug Trial Radar · NCT00174915
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
Last checked: Nov 20, 2026Latest source record: Feb 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,072
Actual
Start
Feb 2003
Primary completion
Apr 2004
Study completion Apr 2004
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout.
Conditions
- Gout
Interventions
FebuxostatDrug
Febuxostat 80 mg, orally, once daily for up to 28 weeks.
FebuxostatDrug
Febuxostat 120 mg, orally, once daily for up to 28 weeks.
FebuxostatDrug
Febuxostat 240 mg, orally, once daily for up to 28 weeks.
AllopurinolDrug
Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine \>1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
PlaceboDrug
Placebo, orally, once daily for up to 28 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL).Time frame: Last 3 visits (any last 3 visits up to week 28)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.